PHS 2022-1 topic 440 - cancer prevention & diagnosis technologies for low-resource settings
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00060
- Awardee
-
Amplifidx Inc. UEI XAAGYAVXZM43
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $400,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $400,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 12 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Francisco, CA 94143, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $400,000 |
About this award
This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR Phase I award, it provides up to $225,000 in funding for initial feasibility and development work, with potential for additional Phase II funding up to $1.5 million for further advancement. Amplifidx, a manufacturer of molecular point-of-care diagnostic devices, will conduct this R&D work domestically.
Quick answers
Who was awarded contract 75N91022C00060?
75N91022C00060 was awarded to Amplifidx Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2022.
How much is contract 75N91022C00060 worth?
The government has obligated $400,000 on 75N91022C00060.
Was contract 75N91022C00060 competed?
The extent of competition for 75N91022C00060 was full and open competition after exclusion of sources. The government received 12 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award